Middle East Pharmaceutical Industries バランスシートの健全性
財務の健全性 基準チェック /56
Middle East Pharmaceutical Industries has a total shareholder equity of SAR337.2M and total debt of SAR30.1M, which brings its debt-to-equity ratio to 8.9%. Its total assets and total liabilities are SAR466.0M and SAR128.8M respectively. Middle East Pharmaceutical Industries's EBIT is SAR91.0M making its interest coverage ratio 17. It has cash and short-term investments of SAR21.6M.
主要情報
8.9%
負債資本比率
ر.س30.13m
負債
| インタレスト・カバレッジ・レシオ | 17x |
| 現金 | ر.س21.63m |
| エクイティ | ر.س337.15m |
| 負債合計 | ر.س128.80m |
| 総資産 | ر.س465.96m |
財務の健全性に関する最新情報
更新なし
Recent updates
財務状況分析
短期負債: 4016's short term assets (SAR295.0M) exceed its short term liabilities (SAR107.6M).
長期負債: 4016's short term assets (SAR295.0M) exceed its long term liabilities (SAR21.2M).
デット・ツー・エクイティの歴史と分析
負債レベル: 4016's net debt to equity ratio (2.5%) is considered satisfactory.
負債の削減: Insufficient data to determine if 4016's debt to equity ratio has reduced over the past 5 years.
債務返済能力: 4016's debt is well covered by operating cash flow (346.6%).
インタレストカバレッジ: 4016's interest payments on its debt are well covered by EBIT (17x coverage).